Dentons is a global law firm supporting life sciences organizations worldwide.
Dentons is uniquely positioned to support the life sciences sector with a combination of global reach, deep industry expertise, and an unwavering focus on client outcomes. As the largest global law firm, Dentons delivers exceptional legal services through more than 12,000 professionals in 160+ locations across 80 countries, ensuring clients receive support wherever their business operates.

By restoring upstream myeloid competence, EXL01 addresses a central bottleneck in immuno-oncology: resistance driven by dysfunctional innate immunity. Preclinical and translational data demonstrate enhanced interferon signaling, improved antigen presentation, and deeper, more durable ICI responses without triggering systemic inflammation.

Dentons’ approach is centered on client priorities. Rather than organizing services around traditional legal silos, Dentons structures its teams and content to align with the needs of clients and the operational realities of their industries.

From R&D and clinical trials to regulatory compliance, intellectual property, transactions, and disputes, Dentons supports clients through the full lifecycle of their products and operations. The firm’s lawyers combine legal knowledge with a sophisticated grasp of the scientific and economic data that underpin key decisions in healthcare and life sciences.

Voisin Consulting Life Sciences (VCLS) is a global consulting organization, with customized CRO abilities dedicated to guiding innovators through the development of HealtTtech products from concept to patient access

We are supporting innovative development like orphan drugs, ATMPs, Oncology, Immunology, Combination product and microbiome therapies, for 30 years with deep expertise to reduce time to key success taking advantage of new regulations and interaction with Health Authorities

With deep expertise in  we help biotech and pharma design derisked smarter, faster, and efficient development pathways.

Our experts optimize non‑clinical, CMC, clinical, regulatory, and market access strategies to accelerate evidence generation and reduce time to key milestones, taking advantage of new regulations and interaction with Health Authorities

AzurBio is the partner of choice for biopharma companies looking to launch their innovation in rare or serious diseases in the European market.

With a dual presence in the US and Europe, AzurBio supports North American companies in accessing the EU market by maximizing flexibility and minimizing operational burden.